Activity of cabozantinib after immunotherapy in advance kidney cancer

A retrospective study published in the European Journal of Cancer this month looked at the activity of cabozantinib after immune checkpoint inhibitors in people with metastatic clear cell renal cell carcinoma (RCC). The overall response rate was 36%, with a median overall survival of 13 months. Cabozantinib appeared to be well tolerated and there were […]

read more

Potential biomarker for response to nivolumab for kidney cancer

Nivolumab was the first immunotherapy to be approved for the second-line treatment of metastatic renal cell carcinoma (RCC). Although some patients have long-lasting responses to nivolumab, others have limited benefit and the majority of patients will eventually experience disease progression. There has been a lot of research to identify a biomarker for response to nivolumab, […]

read more

Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors

This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor. Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint […]

read more

ASCO 2020: Implications of the research presented at ASCO 2020 on the treatment of advanced kidney cancer

In this video presentation, Dr Toni Chouieri discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies, all of which were presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Programme. COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma […]

read more

Combination immunotherapy plus VEGFR inhibitor for favourable risk and elderly kidney cancer patients

A study published in Clinical Genitourinary Cancer this month looks at treating patients with favourable risk metastatic renal cell carcinoma (RCC) and elderly patients with a combination of immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors and VEGFR inhibitors are the most commonly used medications for […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

COVID-19 outcomes in patient with cancer on anti-cancer treatments

Back in March at the start of the COVID-19 pandemic in the UK, people taking chemotherapy, immunotherapy or protein kinase inhibitors for treatment of their cancer were considered to be extremely vulnerable to coronavirus infection and were asked to shield for 12 weeks. At the time, since cancer and its treatments can lower your ability […]

read more

ASCO 2020: Lenvatinib plus pembrolizumab for disease progression after immunotherapy for metastatic kidney cancer

Results from a phase II trial of a combination of lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) which was not responding to treatment with immune checkpoint inhibitor therapy was presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend. One hundred and four (104) patients […]

read more

Safety and efficacy of immunotherapy rechallenge in patients with kidney cancer

There are a number of immune checkpoint inhibitor drugs available for the treatment of people with metastatic renal cell carcinoma (RCC), but the efficacy and safety of treating patients with two separate lines of immunotherapy (rechallenge) is unknown. This study looked at the safety and efficacy of rechallenge with an immune checkpoint inhibitor in patients […]

read more
Showing 1 to 10 of 219 results
  TOP